Navigation Links
Basic Science Discoveries Yield Progress in Hepatology
Date:4/25/2008

Advances in Virology Translate Into New Promising Drugs to Combat Hepatitis

C

Clarification of Oncogenic Pathways Aids Liver Cancer Research

Stem Cells of Potential Benefit in Liver Transplantation

MILAN, April 26 /PRNewswire/ --

- Systems Biology Helps to Solve Complex Liver Diseases

At today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), experts reported advances in basic research that have important implications for the eventual treatment of people with chronic liver diseases.

The goal of basic or "fundamental" biomedical science is to gain knowledge and understanding for its own sake, without reference to a particular practical problem. "Translational" science transforms basic knowledge into practical terms. "Applied" research, such as "clinical trials," takes the discoveries of basic research even further and uses them to solve specific, clearly defined medical problems. Basic, translational, and applied research are each necessary to progress in medicine, including Hepatology.

In virology, for example, notable progress has been made in clarifying the structure of the Hepatitis C virus (HCV), leading to the development of new experimental drugs such as protease inhibitors and polymerase inhibitors, drugs that inhibit virus production. Some of these drugs have been extensively tested and some are currently in phase II trials. Based on results to date, it is clear that these drugs can be highly effective in combination with pegylated Interferon and Ribavirin. Phase III trials are planned.

Important basic science advances in genetics and systems biology have also been reported, offering potential progress for strategies to treat hepatocellular carcinoma (HCC). Using genomics and microarrays to determine gene expression, scientists have discovered that there are different biological pathways - called "oncogen
'/>"/>

SOURCE EASL - European Association for the Study of the Liver
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
2. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
3. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
7. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
8. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
9. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
10. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
11. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... WOODCLIFF LAKE, N.J. and STAMFORD, ... the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and ... into a worldwide collaboration agreement for the development and ... a dual orexin receptor antagonist entering Phase III clinical ... Under the terms of the agreement, Eisai and Purdue ...
(Date:8/31/2015)... Australia , Aug. 31, 2015 Bionomics ... discovery and development of innovative therapeutics for the treatment ... cancer, today announced that its BNC101 IND submission has ... (FDA). Bionomics plans to initiate a Phase 1 clinical ... patients with metastatic pancreatic cancer prior to 31 December ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... labels and stickers to keep little ones' safety top of mind at all times. ... a particular focus. According to the JPMA's Baby Safety Zone website, this year's theme ...
(Date:9/1/2015)... ... 2015 , ... Curly Hair Solutions™ is thrilled to partner ... partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution of ... Curly Hair Solutions™ team could not be more delighted to see their line ...
(Date:8/31/2015)... ... 01, 2015 , ... Spinal fusion surgery – which connects ... long, arduous recovery. However, today’s minimally invasive fusions achieve similar results as traditional ... muscle damage. These advantages of minimally invasive surgery redeem the procedure’s reputation, according ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... potential patients the resources they need to have a successful cosmetic procedure; from ... plastic surgeons; Cosmetic Town Journal is always ready to help. , It is ...
(Date:8/31/2015)... ... , ... Southern Vacation Rentals – a member of the locally owned and ... property management company, 360 Blue, in support of the Sonder Project, a global ... two companies will collect any unopened food items left in vacation rentals after guest ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3
... (May 12, 2008) The Virginia Commonwealth University School ... $6 million from the National Institutes of Healths National ... polycystic ovary syndrome, a disorder of the endocrine system ... Polycystic ovary syndrome, or PCOS, causes hormonal imbalances leading ...
... impact and other influences are limiting the growth ... of frequency and severity of ... AOC ),the leading provider of global risk management and consulting ... care industry,finding for the first time in nine years of ...
... ... oxide material., DENVER, May 12 C5 Medical Werks, ... has submitted a 510(k),pre-market notification to the U.S. Food and ... CAD/CAM Blocks.,ZirDent(TM) is a zirconium material ideally suited to meet ...
... proposals, to expand oral health care services; awards two significant oral ... ... 12 As part of the Illinois,Children,s Healthcare Foundation,s (ILCHF) $20 million, ... is pleased to announce a request for proposals in the oral,health care ...
... games throughout the ... region, PHILADELPHIA, May ... cosponsor the Senior Games, held at,dozens of locations throughout the five-county Philadelphia region. ... each,county, beginning Monday, May 12 and continuing through the month of June.,More than ...
... trial in bladder cancer exceeds 2/3rds enrolment level ... pre-clinical work in peritoneal cancers -, BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, is ... non-clinical development of its proprietary platform technology:,Mycobacterial Cell ...
Cached Medicine News:Health News:NIH grant to support Translational Research Center for PCOS 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 3Health News:C5 Medical Werks Applies for Clearance, Certification and Licensing for the Global Marketing of ZirDent(TM) Ceramic CAD/CAM Dental Blocks 2Health News:Children in Illinois to Have Healthier Smiles 2Health News:Independence Blue Cross Supports 2008 Senior Games 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 3Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 4
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: